Quarterly ResultMay 4, 2026, 09:22 AM
Pulse Biosciences Accelerates NANOPULSE-AF Enrollment; Q1 Net Loss $18.6M
AI Summary
Pulse Biosciences announced accelerated enrollment timelines for its NANOPULSE-AF pivotal clinical trial, now expected to complete by early-Q4 2026, and continued progress in the NANOCLAMP-AF trial. The company reported preliminary financial results for Q1 2026, including a net loss of $18.6 million on $0.4 million in product revenue. As of March 31, 2026, cash and cash equivalents stood at $68.3 million, with $14.6 million used in operating activities during the quarter. The company also highlighted positive clinical data for its nPulse Cardiac Catheter System and key leadership additions.
Key Highlights
- Accelerated enrollment timeline for NANOPULSE-AF pivotal clinical trial, now expected to complete by early-Q4 2026.
- NANOCLAMP-AF pivotal trial enrollment expected to complete by the end of the first half of 2027.
- Preliminary Q1 2026 net loss of $18.6 million, compared to $16.8 million in Q1 2025.
- Q1 2026 product revenue totaled $0.4 million from nPulse Vybrance capital and disposables.
- Cash and cash equivalents were $68.3 million as of March 31, 2026.
- Net cash used in operating activities for Q1 2026 was $14.6 million.
- Presented data showing 90% Kaplan-Meier estimate of freedom from atrial arrhythmias at 12 months for nPulse Cardiac Catheter System.
- Granted inducement options for 15,000 shares to four new employees at an exercise price of $20.83 per share.